Abstract
Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.
| Original language | English |
|---|---|
| Pages (from-to) | 459-471 |
| Number of pages | 13 |
| Journal | Expert Opinion on Drug Safety |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2012 |
Fingerprint
Keywords
- Emerging therapy
- Obesity management
- Orlistat
- Rimonabant
- Sibutramine
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Anti-obesity drugs : A review about their effects and their safety. / Derosa, Giuseppe; Maffioli, Pamela.
In: Expert Opinion on Drug Safety, Vol. 11, No. 3, 05.2012, p. 459-471.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-obesity drugs
T2 - A review about their effects and their safety
AU - Derosa, Giuseppe
AU - Maffioli, Pamela
PY - 2012/5
Y1 - 2012/5
N2 - Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.
AB - Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.
KW - Emerging therapy
KW - Obesity management
KW - Orlistat
KW - Rimonabant
KW - Sibutramine
UR - http://www.scopus.com/inward/record.url?scp=84860163107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860163107&partnerID=8YFLogxK
U2 - 10.1517/14740338.2012.675326
DO - 10.1517/14740338.2012.675326
M3 - Article
VL - 11
SP - 459
EP - 471
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 3
ER -